{"id":"rfsh-drug-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/bloating"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL157030","moleculeType":"Small molecule","molecularWeight":"883.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rFSH is a recombinant version of the naturally occurring follicle-stimulating hormone, a gonadotropin produced by the pituitary gland. It binds to FSH receptors on granulosa cells in the ovary, promoting follicular development and estrogen production. This is used in assisted reproductive technology to induce controlled ovarian hyperstimulation for egg retrieval.","oneSentence":"rFSH (recombinant follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:56.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility in women undergoing assisted reproductive technology (ART)"},{"name":"Anovulation and ovulatory disorders in women"}]},"trialDetails":[{"nctId":"NCT06199960","phase":"PHASE3","title":"Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-08-02","conditions":"Assisted Reproductive Techniques","enrollment":116},{"nctId":"NCT02412904","phase":"PHASE4","title":"Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-01","conditions":"Infertility","enrollment":188},{"nctId":"NCT00374634","phase":"PHASE4","title":"Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination","status":"COMPLETED","sponsor":"Nina la Cour Freiesleben","startDate":"2006-09","conditions":"Infertility","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rFSH drug dose","genericName":"rFSH drug dose","companyName":"Nina la Cour Freiesleben","companyId":"nina-la-cour-freiesleben","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rFSH (recombinant follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory disorders in women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}